Introduction
Lentiviral vectors have great potential as gene therapy vectors. [1] [2] [3] For clinical studies and other gene therapy applications, it is essential to accurately determine the functional titers of lentiviral vectors. For the purpose of this report, functional titer refers to the concentration of vector particles capable of transducing a target cell. Currently a variety of methods for assessing titer are available, but a comprehensive study of lentiviral titer methodology has not been performed. [4] [5] [6] [7] [8] [9] [10] [11] Lentiviral vectors possess many characteristics similar to murine-based retroviral vectors, but their production methods often differ significantly (transient transfection versus packaging cell lines, respectively). 12, 13 The transient transfection methods used for lentiviral vectors pose unique chal- lenges for titering as they often lead to contamination of vector supernatants with plasmid DNA. Current options for titering lentiviral vectors include assessment of vector RNA in supernatant (RNA titer), 14 assessment of vector DNA in transduced cells (DNA titer), and expression of a transgene following transduction. 12, 15, 16 Assessing titer in vector supernatants is technically the easiest and provides the most rapid turnaround. Unfortunately, a RNA titer may not accurately reflect the functional titer due to the presence of defective interfering particles, inhibitors of transduction, and carry over DNA from vector production. 10, 17, 18 Vector expression in transduced cells, particularly when the vector expresses a transgene such as GFP, is technically simple and can estimate functional titer. 16 The limitations of this method are two-fold: it assumes that the level of expression of all integrated vectors is above the detection threshold of the assay and it may not distinguish cells with multiple copies of vector. The most rigorous, and time-consuming, titering method is detection of vector DNA integration in transduced cells. 8, 9 This does not rely on vector expression and will detect multiple vector integrations.
As lentiviral vectors approach clinical application, we sought to define a titering method that provides accurate assessment of functional titer. We therefore developed a real-time PCR assay for detecting lentiviral packaging sequences of HIV1 and used it to quantitate vector DNA molecules in transduced cells (DNA titer). We hypothesized that the most rigorous assay would be assessment of transduced cells 14 days after transduction, alleviating concerns regarding carry-over of plasmid DNA from production. However, as this method is time-consuming, we also evaluated DNA titers 4 days after transduction, and RNA titers directly from the vector supernatant. The DNA and RNA titers were compared with titers obtained from a commonly used expression titer method using the GFP transgene (GFP titer). 19 Not unexpectedly, GFP titers underestimate, and RNA titers overestimate, the number of functional vector particles in supernatants. We conclude that DNA titers provide a more reliable estimate of functional titers than GFP or RNA titers and that the real-time PCR method described here can be used to rigorously assess the DNA titers of most lentiviral vectors derived from HIV-1, regardless of transgene.
Results
To define an optimal titering method for lentiviral vectors, we were interested in comparing three methods (RNA, DNA, GFP expression) of titering ( Figure 1 ). To this end, we first developed a quantitative real-time PCR method for rapid DNA and RNA titer estimation.
Design of lentiviral probe and primers for real-time PCR
For amplification of lentiviral vector DNA, we designed real-time PCR probes and primers in the packaging and primer binding site (PBS) region of HIV1. The packaging/PBS region was chosen for probe design as this essential region is present in most lentiviral vectors derived from HIV1 and could therefore be used for amplification and titering of a variety of vectors. Two sets of lentiviral probes (LV1, LV2) and primers were designed by using the Primer Express software ( Figure  2a) . Amplification of lentiviral vector plasmids with the two probes and primer sets indicated that better amplification kinetics, and less non-specific background, were obtained with the LV2 probe (data not shown). Therefore, all subsequent lentiviral sequence analysis was conducted with the LV2 probe. BLAST analysis with the nucleotide data base indicated that the sequences of LV2 and the corresponding PCR primers FPLV2/RPLV2 have 100% homology to sequences present in the HIV1 genome (Genbank acc No. NC-001802) and common vectors derived from HIV1. 15, 16 The LV2 probe and the corresponding primers result in the amplification of a 145 bp product.
Functional DNA titer of RRL-CMV-GFP vector by realtime PCR
As different cells exhibit different transduction efficiency, and as functional titers are calculated based on this transduction efficiency, we sought to identify the optimal cell line for assessing vector titer. For these studies we utilized the RRL-CMV-GFP lentiviral vector which expresses the GFP gene under the control of the CMV promoter (Figure 2b) . 16 Serially diluted vector supernatant was used to transduce 293, HeLa and Mus dunni cells and genomic DNA was extracted at 4 and 14 days after transduction and analyzed by real-time PCR. The pRRL-CMV-GFP vector plasmid at different concentrations was used to generate a standard curve ( Figure 3 ). The vector plasmid was chosen as a standard as it is possible to measure the concentration of the plasmid accurately by spectrophotometry. The standard curve was then used to determine the number of vector molecules in transduced 293, HeLa or Mus dunni cells 4 and 14 days after transduction. The number of RRL-CMV-GFP molecules at 14 days after transduction exhibited a linear relationship with vector dilution in all three cell lines tested ( Figure 4 ). The highest number of vector molecules was found in the 293 cell line suggesting that this cell line has the highest transduction efficiency ( Figure 4 ). The DNA titer for RRL-CMV-GFP vector in 293 cells was calculated from the plasmid standard curve to be 2.52 ± 0.25 × 10 6 molecules/ml. The DNA titers for RRL-CMV-GFP in HeLa and Mus dunni cells at 14 days after transduction are shown in Table 1 . The number of vector molecules in 293, HeLa and Mus dunni cells 4 days after transduction also exhibited a linear relationship with vector dilution, and 293 cells again showed the highest transduction efficiency (data not shown). The 4-day DNA titers for RRL-CMV-GFP vector were very similar to the 14 day titers in all the cell lines tested (Table 1) . These results suggest that DNA titers can be determined accurately 4 or 14 days after transduction.
As titers estimated by real-time PCR are dependent on the accuracy of the standard curve, DNA titers were also measured using an independently prepared, second batch of pRRL-CMV-GFP plasmid standard and were
Figure 2 (a) Probes and primers used for real-time PCR analysis of lentiviral sequences. Probes (LV1, LV2) were designed in the primer binding site (PBS)/packaging (psi) region of HIV1 vectors and the primers (FPLV2/RPLV2, FPLV1/RPLV1) were designed to amplify the entire PBS/psi region. (b) Structural elements of HIV1 vectors RRL-CMV-GFP, RRL-PGK-GFP and SMPU-RRE-BN. All three vectors are self-inactivating vectors (SIN) with modified LTRs, packaging signal, and rev response element (RRE). The GFP marker gene is expressed under the CMV promoter in RRL-CMV-GFP and under the PGK promoter in RRL-PGK-GFP. The SMPU-RRE-BN vector has a non-expressing ␤gal-neo marker transgene and the central polypurine tract/central termination sequence (cPPT/CTS).
found to be very similar to the titers reported in Table 1 (data not shown). These results suggest that the Taqman assay for determining DNA titers is reproducible and reliable.
Functional GFP titer of RRL-CMV-GFP vector
To determine functional GFP titers, a portion of vector transduced cells used for DNA titering were assessed by FACS analysis for GFP expression. The GFP expression was highest in 293 cells confirming our DNA titer findings that this cell line has the highest transduction efficiency ( Figure 5 ). Also in line with our DNA titer results, GFP titer results did not vary significantly between 4 and 14 days post transduction, suggesting that either time-point can be used for titering by these methods ( Table 1) .
Detection of plasmid DNA in RRL-CMV-GFP transduced cells
Interestingly, comparison of DNA and GFP titers indicated that the DNA titers are approximately 10-fold higher than the GFP titers (Table 1) . To determine if the higher DNA titer was due to carry-over of plasmid DNA used in vector production, we developed a real-time PCR method that detects the ampicillin resistance (amp r ) gene present in most plasmids. Analysis of genomic DNA from RRL-CMV-GFP transduced cells for amp r gene indicated that there were minimal amp r sequences at 4 and 14 days after transduction in all cell lines tested (~0.5-7 × 10 4 molecules/ml). In contrast, analysis of RRL-CMV-GFP vector supernatants directly for amp r sequences
Gene Therapy indicated a large amount of plasmid background (1.4 ± 0.4 × 10 9 molecules/ml). These results suggest that Ͻ0.01% of the plasmid DNA present in vector supernatants is transferred to cells upon vector transduction. Corrected DNA titers obtained by subtracting out the amp r plasmid background were very similar to the uncorrected DNA titers in all cell lines suggesting that the total plasmid present in transduced cells as a result of carry-over from production has little effect on RRL-CMV-GFP DNA titers (Table 1) .
RRL-CMV-GFP vector RNA titers by real-time PCR
Published methods demonstrate that retroviral vector titers can be determined directly by measuring viral RNA sequences in vector supernatants. [4] [5] [6] 9 However, the RNA titers thus obtained may overestimate the number of functional vector particles due to the presence of defective interfering particles and packaging cell line DNA. 10, 17, 20 Also, as shown by our studies above with the amp r PCR assay, carry-over of plasmid DNA is of concern in vectors produced by transient transfection methods.
To compare RNA titers with DNA and GFP titers, we analyzed DNase-treated RNA isolated from RRL-CMV-GFP vector supernatants. In order to compare RNA and DNA titers we used the same pRRL-CMV-GFP plasmid controls to establish our standard curves. RNA concentration was determined by subtracting plasmid copy number in reactions run without reverse transcriptase (RT) from reactions run with RT, to eliminate background due to residual plasmid DNA. As shown in Figure 6 , ser- ial dilutions of vector supernatant exhibited a linear relationship with the amount of vector RNA detected. The number of vector molecules detected by the RNA assay was approximately 1000-fold higher than that observed by the DNA titer method (Table 2 ). This suggests a considerable disparity between the number of vector sequences and the number of vector particles capable of successfully transducing target cells.
Lentiviral probe and primers can be used to measure DNA titers of HIV1 derived vectors
To show that the lentiviral packaging sequence probe and primers can be used for determining titers of a variety of HIV1-based vectors, we measured the DNA, RNA and GFP titers of the RRL-PGK-GFP vector ( Figure 2b and Table 2 ). All three methods indicated that the titer was lower for this vector than that obtained for the RRL-CMV-GFP vector. The PCR probe and primers also detected titer of a vector with a different backbone, the SMPU-RRE-BN vector ( Figure 2b and Table 2 ) (Barcova and Cannon, manuscript in preparation). The SMPU-RRE-BN is a marker vector, which contains a nonexpressive transgene and illustrates the utility of this PCR system in situations where molecular methods are the only means of assessing vector transduction.
Discussion
In order to define an optimal functional titering method for lentiviral vectors, we have developed a quantitative real-time PCR method for DNA titering and conducted a comparative analysis of DNA, RNA and GFP titering methods. We conclude that DNA titers may provide a more reliable estimate of functional titers than GFP or RNA titers and that the real-time PCR method described can be used to determine titers of a variety of HIV1 vectors.
As functional titers are dependent on transduction efficiency, we measured DNA and GFP titers of the lentiviral vector, RRL-CMV-GFP, in three different cell lines (293, HeLa, Mus dunni). Our results suggest that 293 cells are optimal for titering as they exhibit the highest transduction rate.
We also measured DNA titers at two time-points after transduction to assess the effect of carry-over plasmid DNA on titers. Carry-over of DNA is a major concern for transient production methods frequently used to generate lentiviral vectors. Our results show that the 4-and 14-day RRL-CMV-GFP titers are similar in all cell lines tested, suggesting that there is not a significant amount of vector plasmid at 4 days. This was further confirmed by direct measurement of ampicillin containing plasmid molecules in vector transduced cells 4 and 14 days after transduction. We therefore conclude that DNA titers can be determined accurately in 293 cells 4 or 14 days after transduction.
Our results also indicate that the DNA titers of RRL-CMV-GFP and RRL-PGK-GFP vectors are higher than the GFP titers and that the higher DNA titers are not due to background vector plasmid in transduced cells. The DNA and GFP titers at 4 days (4D), and 14 days (14D) after transduction are shown. DNA titers are represented as the number (#) of vector DNA molecules/ml vector supernatant and were calculated by real-time PCR using pRRL-CMV-GFP vector plasmid as a standard. The GFP titers are shown as number of GFP-positive cells/ml of supernatant and were determined by FACS analysis of transduced cells. The 4 and 14D titers are similar to each other and the DNA titers are~10-fold higher than the GFP titers. Corrected DNA titers were obtained by subtracting out the amp r plasmid background from DNA titers at 4 and 14 days after transduction. Amp r background was determined by real-time PCR with an amp r probe. In all cell lines, the corrected and uncorrected DNA titers appear to be similar. lower GFP titers could be related to a lack of GFP expression by a portion of the integrated vectors. Also, cells expressing low levels of GFP may not be detected by FACS analysis. GFP titers may additionally be dependent on the nature of the promoter used to express the GFP gene. A weaker promoter may lead to a lower GFP expression and a lower GFP titer, resulting in a higher difference between DNA and GFP titers. This effect of promoters would explain the~60-fold higher DNA titer of RRL-PGK-GFP compared with the GFP titer. In contrast, the DNA titer of RRL-CMV-GFP, where the GFP expression is driven by the stronger CMV promoter, is only~10-fold higher than the GFP titer in 293 cells. GFP expression titers may therefore, underestimate the actual number of functional vector particles in supernatants. The DNA titers on the contrary are more quantitative as they detect all vector molecules in transduced cells and are determined using a plasmid standard that can be measured precisely. DNA titers may therefore provide a more reliable estimate of functional titer than GFP titers. We have also used real-time PCR with the lentiviral packaging probe to determine RNA titers directly from vector supernatants. Our results show that the RNA titers for RRL-CMV-GFP and RRL-PGK-GFP are significantly higher than the DNA and GFP titers. The higher RNA titers are most likely due to the presence of defective interfering particles or inhibitors of transduction in vector supernatants. They do not appear to be due to plasmid DNA, as we conducted PCR analysis of supernatants in Table 2 DNA, GFP and RNA titers of HIV1 derived vectors the presence and absence of reverse transcriptase to eliminate DNA background as explained in Materials and methods. Our results therefore reinforce the observation that RNA titers from supernatants overestimate the actual number of functional vector particles. DNA titers in comparison provide a more accurate estimation of functional vector particles as they measure vector particles that transduce cells. Also, DNA-PCR can be used to measure low titer vectors whereas the RNA method, due to the presence of background plasmid, may be unsuitable for measuring low titer vectors. Nevertheless, the RNA method could be used for comparative analysis of production supernatants when screening for material with moderate to high titers. 4, 5 In conclusion, of the three methods tested, titers assessed by DNA analysis of transduced cells provide a reliable estimate of functional titers as they account for factors such as defective interfering particles, vector expression levels, and plasmid contamination. The realtime PCR method described here can also be used for functional titer determination of a wide variety of vectors irrespective of transgenes.
Figure 5 Transduction efficiency of 293, HeLa and Mus dunni cells with RRL-CMV-GFP at 4 days (a) and 14 days (b) after infection as a function of vector dilution. Transduction at each dilution was done in triplicate and the % GFP fluorescent cells determined by FACS analysis. (c) Selection of GFP-positive cells in vector transduced 293 cells. Quadrants were placed consistently to include GFP-positive cells with fluorescence signals above the background cell fluorescence of untransduced 293 cells shown in the left dot plot. GFP-positive cells in vector-transduced HeLa and Mus dunni cells were similarly selected. The GFP titers were determined by multiplying the frequency of fluorescent cells with vector dilution as described in the Materials and methods.

Materials and methods
Cell lines and constructs
Human 293, Mus dunni, and HeLa cells were obtained from ATCC. 293T cells for vector production were obtained from Cell Genesys (Foster City, CA, USA). 293 and 293 T cells were maintained in D-10 medium (high glucose Dulbecco's modified Eagle's medium with 10% FBS supplemented with 2 mM/l L-glutamine, 1 mM/l Na pyruvate, and 1% penicillin/streptomycin solution). HeLa cells were maintained in modified Eagle's medium with 10% FBS and 1% nonessential amino acids (GIBCO). Mus dunni cells were maintained in M10 (McCoys 5A with 10% FBS and 1% penicillin/streptomycin solution, GIBCO). For roller bottle production of vectors, 293T cells were maintained in IMDM + 10% FBS (GIBCO). The selfinactivating vector constructs pRRL-CMV-GFP/pRRL-PGK-GFP, the packaging construct pMDL, the rev construct pRSV-rev, and the VSVG expressing construct pMDG were all obtained from Cell Genesys. 16 The pSMPU-RRE-BN vector construct was obtained from Dr Donald Kohn (Childrens Hospital, Los Angeles, CA, USA). The construct contains a non-expressing ␤gal-neo gene due to the mutations at the start codons. The construct is based on the SMPU vector backbone (Barcova and Canon, manuscript in preparation) and contains in addition, the rev response element (RRE) inserted into the ␤gal-neo gene.
Vector preparation SMPU-RRE-BN vector was prepared by transient transfection of 293T cells with vector DNA, packaging plasmid (pMDL), rev expressing plasmid pRSV-rev, and envelope plasmid pMDG using the calcium phosphate method. 12, 15 Culture supernatant was collected 36-40 h after transfection, filtered through a 0.45-m filter, and stored at -70°C. For production of RRL-CMV-GFP and RRL-PGK-GFP supernatants in roller bottles, a Forma incubator with a Wheaton roller bottle unit was used. The roller bottles were incubated with 150 ml of growth medium (IMDM + 20 mM MgCl 2 + 10% FBS) for 1-2 h at 5% CO 2 and 37°C. 293T cells were seeded at 40-50 × 10 6 cells/850-cm 2 bottle turning at 1 r.p.m. and cells were allowed to reach a confluency of 70-80% for transfection (~24 h). Transfer vector plasmid (pRRL-CMV-GFP/pRRL-PGK-GFP, 150 g), pMDL (75 g), pRSV-Rev (37.5 g) and pMDG (52.5 g) were transfected using the calcium phosphate method. Culture medium was replaced 16-18 h after transfection with 150 ml of vector collection medium (IMDM + 10% FBS) per roller bottle. Vector supernatants were harvested 24 h after media exchange (~40 h after transfection) and filtered through 0.45 m cellulose acetate filter, divided into aliquots and frozen at -70°C. The filtered supernatants were used for transducing 293, HeLa and Mus dunni cells. Ϫ3 , 10 Ϫ4 ) of RRL-CMV-GFP or RRL-PGK-GFP vector supernatants were prepared in D10 medium and incubated with cells for 4 h in the presence of polybrene at 8 g/ml (5% CO 2 , 37°C). Cells were maintained in culture for 4 days, trypsinized, and an aliquot was analyzed for fluorescence with a FACScan (Beckton Dickinson Immunocytometry Systems, San Jose, CA, USA) for 4-day GFP titer. About 10 6 cells from each vector dilution were used for DNA extraction and the remaining cells were transferred to a 75-cm 2 flask to grow until day 14 in D10 medium. At 14 days after transfection, cells were trypsinized, washed and an aliquot was prepared for FACS analysis for 14-day GFP titer and DNA was extracted from the remaining cells. GFP-positive cells in transduced cells were selected as shown (Figure 5c ), and GFP titers at 4 and 14 days were calculated as previously described using the following formula:
GFP titers
19 titer = {F × Co/V} × D. F is the frequency of GFP-positive cells determined by flow cytometry; Co is the total number of target cells infected; V is the volume of the inoculum; D is the virus dilution factor. GFP titers were calculated at several vector dilutions (0, 10
Ϫ3 ), and an average of titer values at vector dilutions corresponding to 1-20% of GFP-positive cells in FACS analysis is reported in Table 1 . Selecting values in this range decreases the chance of analyzing cells with multiple copies of the vector, which would underestimate titer.
PCR titers
Probes LV2 (5'-FAM AGCTCTCTCGACGCAGGACT CGGC-TAMRA), LV1 (5'-FAMCTCGACGCAGGACTCG GCTTGC), amp r P (5'FAM ACGCTCGTCGTTTGGTAT GGCTTCATTC-TAMRA), and primers FPLV2 (ACCT GAAAGCGAAAGGGAAAC), RPLV2 (CACCCATCTCT CTCCTTCTAGCC), FPLV1 (5'GGACCTGAAAGCGAAA Gene Therapy GGG), RPLV1 (5'CATCTCTCTCCTTCTAGCC TCCG) ampFP (GTTGCCATTGCTACAGGCATC), ampRP (ACT CGCCTTGATCGTTGGG) for real-time PCR were designed using the Primer Express software program and obtained from Applied Biosystems (Foster City, CA, USA). For determining DNA titers, genomic DNA from approximately 1-10 × 10 6 vector transduced cells was isolated 4 and 14 days after transduction using the Puregene kit (Promega, Madison, WI, USA). DNA was isolated from cells transduced with several dilutions of vector. Genomic DNA was resuspended in 10 mM Tris with 0.1 mM EDTA (TE), incubated at 65°C for 30 min, vortexed, and stored at 4°C. For real-time PCR analysis, genomic DNA was diluted in TE and 3 l of DNA was mixed with 47 l of a PCR master mix consisting of 1 × TaqMan buffer A, 3.5 mM MgCl 2 , 200 M of each dNTP, 320 nM of each forward primer (FPLV2), and reverse primer (RPLV2), 200 nM of the lentiviral probe (LV2) and 0.025 units/l of ampliTaq Gold. For negative controls, 3 l of TE and 3 l of genomic DNA from untransduced cells were used. All reactions were carried out in triplicate and amplifications were performed using one cycle of 95°C for 10 min, and 35 cycles of 95°C for 15 s and 60°C for 2 min. Amplification of vector plasmid DNA for generation of standard curves was performed using concentrations of plasmids ranging from 10 7 molecules/l to 10 molecules/l as determined by spectrophotometry. Plasmid DNA used for standard curve generation was diluted with genomic DNA from uninfected 293/HeLa/Mus dunni cells to control for any inhibitory effect of genomic DNA on PCR. The number of vector DNA molecules in transduced cells was calculated by comparing threshold cycle (Ct) values of samples to that of the plasmid standard curve. For determining the final DNA titer of vectors, the total number of vector DNA molecules in transduced cells was corrected for dilution and the number of cells plated and infected. The PCR conditions for amplifications using the amp r probe/ primers are identical to the ones used for the lentiviral probe/primer amplifications.
For RNA titers, RNA was isolated from DNase-treated, serially diluted, RRL-CMV-GFP or RRL-PGK-GFP vector supernatants as follows. Vector supernatant (400 l) was treated with Dnase (5 U/ml) for 15 min at room temperature and the enzyme was inactivated by addition of EDTA. The vector supernatant was then serially diluted (10 Ϫ1 , 10 Ϫ2 , 10 Ϫ3 , 10 Ϫ4 ) in IMDM and RNA was extracted from each dilution using RNAeasy columns (Qiagen, Valancia, CA, USA). Purified RNA was resuspended in 50 l of TE and 5 l of RNA was mixed with a master mix containing 1 × ampliTaq Gold buffer, 3.5 mM MgCl 2 , 200 M each of dNTP, 320 nM each of forward and reverse primer, 320 nM of the lentiviral probe, 0.025 U/l of ampliTaq Gold, 0.25 units/l of Moloney murine reverse transcriptase, and 0.4 U/l of Rnase inhibitor. For determining background due to any residual DNA left in the supernatant after Dnase treatment, PCR was also conducted in the absence of reverse transcriptase (RT Ϫ control) by mixing 5 l of purified RNA with 45 l of the above master mix without RT. Amplification was performed using one cycle of 48°C for 30 min, one cycle of 95°C for 10 min, and 35 cycles of 95°C for 15 s and 60°C for 2 min. The RNA titer was determined by using vector plasmid as the standard after subtracting out the background from the RT Ϫ reaction.
